This review aims to critically appraise the unique value of dual SGLT1/2 inhibition, synthesizing evidence on its mechanisms, clinical efficacy, safety, and place in therapy, particularly for patients with heart failure. The gene discussed is SLC5A1; the disease is heart failure.